Literature DB >> 1727280

PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.

L K Griffeth1, F Dehdashti, A H McGuire, D J McGuire, D J Perry, S M Moerlein, B A Siegel.   

Abstract

Positron emission tomography (PET) with fluorine-18 fluoro-2-deoxy-D-glucose (FDG) was performed in 19 patients referred for clinical evaluation of soft-tissue masses. These patients had 20 different lesions and had been evaluated previously with computed tomography (CT) and/or magnetic resonance (MR) imaging. The diagnoses were subsequently confirmed with open biopsy or excision (19 lesions) or by clinical and radiographic follow-up (one lesion). Semiquantitative assessment of FDG accumulation (differential uptake ratio) within the suspected tumor helped correctly separate the 10 malignant tumors from the 10 benign lesions. In contrast, a simple ratio of FDG uptake within the suspected tumor to that within comparable normal soft tissue was less successful in helping make this distinction, with overlap in 12 of the 20 cases. Careful comparison with findings from other available imaging studies is essential for accurate interpretation of PET studies of soft-tissue masses, but in many cases, PET may be a useful adjunct in the preoperative evaluation of suspected soft-tissue tumors, yielding valuable information that is not provided with CT or MR imaging.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727280     DOI: 10.1148/radiology.182.1.1727280

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

1.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; M Tokunaga; Y Koyama; N Sato; K Endo
Journal:  Skeletal Radiol       Date:  2003-01-24       Impact factor: 2.199

2.  FDG-PET: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

3.  Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures.

Authors:  A Schomburg; H Bender; C Reichel; T Sommer; J Ruhlmann; B Kozak; H J Biersack
Journal:  Eur J Nucl Med       Date:  1996-05

Review 4.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 5.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

6.  Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.

Authors:  M H Schwarzbach; A Dimitrakopoulou-Strauss; F Willeke; U Hinz; L G Strauss; Y M Zhang; G Mechtersheimer; N Attigah; T Lehnert; C Herfarth
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

7.  Detection of cancer recurrence in irradiated mandible using positron emission tomography.

Authors:  H Minn; K Aitasalo; R P Happonen
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

8.  Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas.

Authors:  L Kostakoglu; D M Panicek; C R Divgi; J Botet; J Healey; S M Larson; H M Abdel-Dayem
Journal:  Eur J Nucl Med       Date:  1995-11

9.  [Imaging techniques in rheumatology: PET in rheumatology].

Authors:  D Sandrock; M Backhaus
Journal:  Z Rheumatol       Date:  2010-06       Impact factor: 1.372

10.  Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.

Authors:  Rong Tian; Minggang Su; Ye Tian; Fanglan Li; Lin Li; Anren Kuang; Jiancheng Zeng
Journal:  Skeletal Radiol       Date:  2009-02-10       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.